Skip to main content
Premium Trial:

Request an Annual Quote

Tessarae Will Use Affy Arrays to Develop Pathogen-Detection Kit

NEW YORK (GenomeWeb News) — Affymetrix today said Tessarae, a maker of tests to identify infectious diseases, will use its microarrays to develop and market new epidemiological research tests for public health surveillance.  
 
Under the terms of the agreement, Tessarae has non-exclusive rights to Affy’s CustomSeq resequencing arrays to develop kits that will recognize viral and bacterial pathogens based on genotypic signatures.
 
Affy said the arrays have been tailored to detect upper respiratory pathogens from target sequences provided by the US Naval Research Laboratory. The tests will be designed for common pathogens such as those causing respiratory disease and pneumonia, as well as respiratory biothreat agents.
 
Tessarae’s PCR-based kits will be used by public health officials to identify pathogens during an outbreak. Affy said the TessArray RPM-Flu3.0 kits will allow physicians to simultaneously detect particular strains, substrains, and nucleotide changes.
 
Financial terms of the agreement were not released.
 
Tessarae started this program with a $35-million infusion from US Department of Defense. The company patented the platform in November 2006.
 
Tessarae plans to develop test kits for encephalitis, hemorrhagic fever, and other blood-borne infections.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.